Women who take the prescription pill every day have an increased risk of developing prostate cancer, according to a new study.
The research, published in the Canadian Journal of Cancer, looked at more than 1.2 million men and women who took the drug for more than 10 years.
The researchers found that men with prostate cancer who took estrogen-based drugs had a 10-fold increase in the risk of dying from the disease.
In women, the risk was only 5 per cent.
“It is a major public health issue,” said Dr. Robert Fennell, a prostate cancer expert at the University of Toronto’s Scarborough Campus and co-author of the study.
Fennells team followed the men for about two decades.
The men who took ERAs also had an increased rate of prostate cancer.
The risk of death from prostate cancer in men who used ERAs doubled from 8.6 per cent in the baseline to 13.4 per cent after 10 years of taking ERAs, the study found.
It is not clear whether the risk is caused by ERAs or other compounds that are released into the body by the body when it is active.
But Fennels team says it is the first study to demonstrate that men who take ERAs have a higher risk of prostate and colorectal cancer than men who do not.
Fierce debate About 2.6 million Canadian men and 4.4 million women have prostate cancer and the most common cause of death is heart disease.
But some researchers say ERAs could help to curb prostate cancer deaths.
One of the leading theories is that ERAs help the body to produce and use a more powerful type of prostaglandin that protects against prostate cancer cells.
But the research does not appear to be conclusively proven.
Ferenc Rady, a professor at the Karolinska Institute in Stockholm, Sweden, who has conducted studies on the efficacy of ERAs for prostate cancer patients, says he has yet to see any data to support this theory.
“I am not aware of any randomized controlled trials that have looked at this in women,” he said.
Rady also said he is not aware that any ERAs are being prescribed for men, but said the FDA’s guidelines on use of ERCs should be updated to reflect the increased risk.
The FDA’s guidance does not mention ERAs.
Dr. Daniel Roesler, a senior research fellow at the Institute of Cancer Research in London, said he had not seen any data showing that ERCs are associated with prostate or colorecolate cancers in men.
“There’s no clear evidence that ERIs cause cancer in man,” he wrote in an email.
“What is clear is that they are an effective treatment for cancer and we should continue to use them.”
Women who are concerned about their health have the option of using an oral contraceptive, or a hormone-based treatment called progestin, said Fennills team.
He said he was surprised by the study’s findings.
Women who do use ERAs should get counseling about the risks and benefits of their medicines, and also consider taking birth control, he said, and talk with their doctor about the side effects.
Fennerell said he did not know if ERAs cause prostate cancer because his team did not have data to study the link.
Fertilizer-based treatments are often the first choice for men who are in the early stages of prostate or cervical cancer.
There are two common types of progestins, and estrogen is the preferred hormone for most men who have prostate or colon cancer.
It also is used for prostate and colon cancer, but studies are not yet available to confirm that it is safe for men with both types of cancers.
Men with more aggressive cancers, such as prostate and pancreatic, are more likely to take ERIs.
They are also less likely to need to take other forms of treatment, such use of estrogen-only medicines or corticosteroids.
“We need to be cautious about prescribing ERAs because they can cause side effects and we need to have a good understanding of the benefits and risks of these medicines,” Fennill said.
“And I would also encourage all men to be aware of the side effect profile of their medications, and to be vigilant about taking them as directed.”
The new study comes as prostate cancer treatment in Canada is on the rise.
The number of men in the country seeking treatment for the disease has increased to nearly 30,000 in recent years, with about 4,000 new cases diagnosed each year.
Fears that ERA use could lead to more aggressive prostate cancer has prompted the Canadian government to review the use of the drug and to make it easier for women to obtain the medicine.
In a letter to the Public Health Agency of Canada, Dr. David R. Rauch, the head of the Canadian Paediatric Society, said the drug’s increased use and the “potential for increased